Joseph Alvarnas, MD, Discusses New CMS Drug Pricing Models, Impact for Blood Diseases

CMS in February 2023 announced 3 new models for testing by the Center for Medicare & Medicaid Innovation—all of which “aim to lower the cost of drugs, promote accessibility to life-changing drug therapies, and improve quality of care.”

Related Keywords

California ,United States ,Joseph Alvarnas ,Reuters ,National Cancer Institute ,Centers For Medicare Medicaid Services ,Coverage Under Evidence Development ,National Institutes Of Health ,Medicaid Innovation ,Gene Therapy Access Model ,Accelerating Clinical Evidence Model ,Based Oncology ,Editor In Chief Joseph Alvarnas ,Gene Therapy Access ,Evidence Development ,Gene Therapy Model ,Infect Agent ,Gene Therapies ,Sickle Cell ,Rare Blood ,Pricing Models ,Cms ,